{
    "eid": "2-s2.0-85148507055",
    "title": "Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Axicabtagene ciloleucel",
        "chimeric antigen receptor (CAR) T-cell therapy",
        "cytokine release syndrome (CRS)",
        "immune effector cell-associated neurotoxicity syndrome (ICANS)",
        "large B-cell lymphoma (LBCL)"
    ],
    "authors": [
        "Karthik Nath",
        "Kitsada Wudhikarn",
        "Ana Alarcon Tomas",
        "Miguel Angel Perales"
    ],
    "citedby-count": 1,
    "ref-count": 109,
    "ref-list": [
        "Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy",
        "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma",
        "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma",
        "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study",
        "Role of CD19 CAR T cells in second line large B cell lymphoma: lessons from phase 3 trials - an expert panel opinion from the American society for transplantation and cellular therapy",
        "Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma",
        "Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial",
        "Long-term (\u22654 Year and \u22655 Year) overall survival (OS) by 12- and 24-Month Event-Free Survival (EFS): an Updated Analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory Large B-Cell Lymphoma (LBCL)",
        "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial",
        "Axicabtagene ciloleucel as second-line therapy for large B-Cell Lymphoma",
        "Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial",
        "Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome",
        "Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia",
        "Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells",
        "CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86",
        "CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade",
        "Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia",
        "Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management",
        "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells",
        "Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy",
        "KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma",
        "Current concepts in the diagnosis and management of cytokine release syndrome",
        "Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium",
        "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma",
        "Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells",
        "The promise of chimeric antigen receptor T cells (CARTs) in leukaemia",
        "FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome",
        "Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma",
        "Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma",
        "Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma",
        "Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy",
        "Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms",
        "The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells",
        "GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts",
        "Chimeric antigen receptor T-cell therapy - assessment and management of toxicities",
        "Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy",
        "Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia",
        "Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells",
        "Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy",
        "Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators",
        "Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier",
        "Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies",
        "Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy",
        "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events",
        "Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease",
        "Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for patients with refractory, aggressive Non-Hodgkin Lymphoma (NHL)",
        "A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma",
        "Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)",
        "Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells",
        "Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia",
        "CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: updated Results From a Phase I Anti-CD22 CAR T-Cell Trial",
        "Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)",
        "Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial",
        "Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies",
        "Toxicities of chimeric antigen receptor T cells: recognition and management",
        "Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma",
        "Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a systematic review and meta-analysis",
        "Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B cell lymphoma",
        "Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL",
        "DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality",
        "Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)",
        "Cardiovascular Effects of CAR T Cell Therapy: a Retrospective Study",
        "Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies",
        "Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma",
        "Cardiac profile of chimeric antigen receptor t cell therapy in children: a single-institution experience",
        "Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy",
        "CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?",
        "CAR T cells-associated delayed lung toxicity\u2013a case series",
        "CD19 CAR-T cell therapy induced immunotherapy associated interstitial pneumonitis: a case report",
        "Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma",
        "Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery",
        "Acute kidney injury after chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia",
        "Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy",
        "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia",
        "Gastrointestinal adverse events observed after chimeric antigen receptor T-cell therapy",
        "Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)",
        "Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection",
        "Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus",
        "The risk of hepatitis B reactivation is controllable in patients with concomitant hepatitis B virus infection during chimeric antigen receptor T-cell therapy",
        "Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma",
        "Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients",
        "Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy",
        "Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma",
        "Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma",
        "Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma",
        "Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma",
        "Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma",
        "State of the CAR-T: risk of infections with chimeric antigen receptor T-Cell therapy and determinants of SARS-CoV-2 vaccine responses",
        "Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells",
        "Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group",
        "Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: a Case Study",
        "COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience",
        "Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis",
        "Invasive fungal infections after anti-CD19 chimeric antigen receptor-modified t-cell therapy: state of the evidence and future directions",
        "How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies",
        "Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)",
        "Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)",
        "Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia",
        "Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy",
        "CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy",
        "Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians",
        "Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper",
        "Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)",
        "Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies",
        "CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma",
        "Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy",
        "G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma",
        "\u2018Save the day with a stem cell rescue\u2019: use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy",
        "Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy"
    ],
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Madrid",
            "@id": "60033237",
            "affilname": "Hospital General Universitario Gregorio Mara\u00f1\u00f3n",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033237",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Institutes of Health",
        "National Cancer Institute"
    ]
}